drotaverine, acephyllinate drug combination: formerly called Depogen, however name is now used for another drug [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 124905 |
| MeSH ID | M0107052 |
| Synonym |
|---|
| depogen |
| 6,7,3',4'-tetraethoxy-1-benzal-1,2,3,4-tetrahydroisoquinoline-theophylline-7-acetate |
| drotaverine acephyllinate |
| DRA , |
| unii-4an25f4w2p |
| 4an25f4w2p , |
| 6,7,3',4'-tetraethoxy-1-benzyl-3,4-dihydro-isoquinoline, xanthine-7-acetate, drug combination |
| drotavarine-theophylline-7-acetate |
| 61954-97-0 |
| drotaverine, acephyllinate drug combination |
| drotaverine acephyllinate [mi] |
| 1-[(3,4-diethoxyphenyl)methyl]-6,7-diethoxy-3,4-dihydroisoquinoline;2-(1,3-dimethyl-2,6-dioxopurin-7-yl)acetic acid |
| (1,3-dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-7h-purin-7-yl)acetic acid--1-[(3,4-diethoxyphenyl)methyl]-6,7-diethoxy-3,4-dihydroisoquinoline (1/1) |
| DTXSID10977496 |
| Q27259347 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " The structural identifiability of the model was proved by computer analysis, and the pharmacokinetic parameters were determined." | ( The fate of drotaverine-acephyllinate in rat and man. II. Human pharmacokinetics of drotaverine-14C-acephyllinate. Deutsch, T; Eckhardt, S; Kerpel-Fronius, S; Szatmári, I; Szüts, T; Vargay, Z; Várkonyi, P, ) | 0.13 |
| "Allometric scaling is an empirical examination of the relationships between the pharmacokinetic parameters and size (usually body weight, ratio of organ- and body weight, breathing number, etc." | ( [Interspecies allometric scaling in pharmacokinetics of drugs]. Sylvia, M, 1998) | 0.3 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Investigations have proved that in the case of po preparations disintegration time, dissolution rate and in vivo absorption rate are closely interrelated." | ( Correlation between disintegration, dissolution and in vivo absorption rate in the case of compounds with benzyl-isoquinoline structures and its pharmacokinetic aspects. Marton, S; Rácz, I; Szentmiklósi, P, ) | 0.13 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " Based on the results obtained and pharmacokinetic properties, the expectable optimal dosage and formulations for the possible field of indication were elaborated." | ( Biopharmaceutical aspects of Depogen. Marton, S; Szentmiklósi, P, 1983) | 0.27 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (50.00) | 18.7374 |
| 1990's | 2 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.96) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (10.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 9 (90.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||